[ad_1]
The average efficacy demonstrated by the Oxford-Astrazeneca-Irbm coronavirus vaccine is 70%. This was announced by the manufacturing company itself.
Two different types of dosages, AstraZeneca explains, have been shown to be effective, with one regimen better than the other. There were no hospitalizations or serious cases of Covid-19 among participants in the AZD1222 vaccine trial.
The data relates to the ongoing trial in Britain and Brazil and shows that the vaccine is “very effective in preventing Covid-19”.
In this analysis, 131 cases of Covid-19 were considered.
The one-dose vaccine regimen was 90% effective: in this case, the vaccine was administered with a half dose, followed by a full dose at least one month apart.
The second regimen followed showed an efficacy of 62%: in this case, two full doses were administered one month apart. Combined analysis of the two regimens yielded a mean vaccine efficacy of 70%. Further analysis will be carried out to establish the duration of protection.
REPRODUCTION RESERVED © Copyright ANSA